Diversity and Inclusion in Rare Disease Clinical Research
Patient diversity and inclusion are essential to rare disease research progress. Why? Because people with the same disease may experience it differently. With a US population comprised of 40% racial and ethnic minorities[1],it’s essential that clinical trials reflect a variety of lived experiences, as well as characteristics like ethnicity, age, and gender, so that all […]
Overcoming Challenges of Incorporating Genetics into Clinical Trial Programs
To date, 760 orphan drugs have been approved by US and European agencies to treat nearly 7,000 identified rare diseases. With 80% having a genetic component, genetic testing and the use of its data have become essential ingredients to the successful diagnosis and treatment of rare diseases. Yet incorporating that genetic data into the clinical […]
High-Touch Approach Streamlines Patient Identification Process in Clinical Trial
Our client, a leading biotech innovator committed to developing revolutionary personalized therapies for dementia and Alzheimer’s disease patients, relies heavily on positive outcomes from its clinical trials. Yet, identifying appropriate patients with the right gene mutation for these trials can be a challenge. When trial sites failed to identify enough patients for a phase 3 […]
